Skip to main content

Table 4 Outcomes at baseline, 4 and 12 weeks — mean (standard deviation)

From: A pilot single-blind parallel randomised controlled trial comparing kinesiology tape to compression in the management of subacute hand oedema after trauma

 

TAU Baseline mean (SD)

TAU 4-week mean (SD)

TAU 12-week mean

TAU mean change baseline—12 weeks (SD)

TT Baseline mean (SD)

TT 4-week mean (SD)

TT 12-week mean (SD)

TT Mean change baseline—12 weeks (SD)

Volumeter (ml)

507.86 (70.23)

490.71 (59.47)

473.57 (60.60)

34.29 (27.75)

505.00 (102.27)

476.43 (103.27)

460.00 (97.47)

45.00 (48.22)

PEM (0–100)

54.17 (16.98)

46.20 (19.39)

38.60 (18.15)

15.57 (18.18)

62.70 (15.61)

44.90 (14.57)

36.31 (16.98)

26.39 (16.40)

ORS (0–6)

3.14 (0.69)

2.43 (0.79)

1.57 (0.79)

1.57 (0.98)

3.57 (0.79)

2.57 (1.13)

2.14 (1.07)

1.43 (1.13)

EQ-5D-5L utilitya(−0.594–1)

0.55 (0.22)

0.65 (0.14)

0.69 (0.21)

0.15 (0.26)

0.64 (0.13)

0.76 (0.13)

0.79 (0.13)

0.16 (0.16)

EQ-5D-5L VASb(0–100)

68.57 (11.80)

70.71 (14.84)

76.43 (15.74)

7.86 (20.18)

68.57 (11.07)

85.00 (12.91)

85.86 (16.30)

17.29 (21.00)

  1. TAU Treatment as usual, TT Trial treatment, SD Standard deviation, PEM Patient evaluation measure, ORS Oedema rating scale, VAS Visual analogue scale
  2. aA higher score (closer to 1) indicates higher quality of life derived health utility
  3. bA higher score indicates better health states